Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 135

1.

Simultaneous angiotensin receptor blockade and glucagon-like peptide-1 receptor activation ameliorate albuminuria in obese insulin-resistant rats.

Rodriguez R, Escobedo B, Lee AY, Thorwald M, Godoy-Lugo JA, Nakano D, Nishiyama A, Parkes DG, Ortiz RM.

Clin Exp Pharmacol Physiol. 2019 Nov 1. doi: 10.1111/1440-1681.13206. [Epub ahead of print]

PMID:
31675433
2.

A once-monthly GLP-1 receptor agonist for treatment of diabetic cats.

Schneider EL, Reid R, Parkes DG, Lutz TA, Ashley GW, Santi DV.

Domest Anim Endocrinol. 2020 Jan;70:106373. doi: 10.1016/j.domaniend.2019.07.001. Epub 2019 Jul 8.

PMID:
31479925
3.

Machine behaviour.

Rahwan I, Cebrian M, Obradovich N, Bongard J, Bonnefon JF, Breazeal C, Crandall JW, Christakis NA, Couzin ID, Jackson MO, Jennings NR, Kamar E, Kloumann IM, Larochelle H, Lazer D, McElreath R, Mislove A, Parkes DC, Pentland A', Roberts ME, Shariff A, Tenenbaum JB, Wellman M.

Nature. 2019 Apr;568(7753):477-486. doi: 10.1038/s41586-019-1138-y. Epub 2019 Apr 24. Review.

4.

Sequencing of human genomes with nanopore technology.

Bowden R, Davies RW, Heger A, Pagnamenta AT, de Cesare M, Oikkonen LE, Parkes D, Freeman C, Dhalla F, Patel SY, Popitsch N, Ip CLC, Roberts HE, Salatino S, Lockstone H, Lunter G, Taylor JC, Buck D, Simpson MA, Donnelly P.

Nat Commun. 2019 Apr 23;10(1):1869. doi: 10.1038/s41467-019-09637-5.

5.

Twentieth-century contribution to sea-level rise from uncharted glaciers.

Parkes D, Marzeion B.

Nature. 2018 Nov;563(7732):551-554. doi: 10.1038/s41586-018-0687-9. Epub 2018 Nov 21.

PMID:
30464265
6.

Simultaneous GLP-1 receptor activation and angiotensin receptor blockade increase natriuresis independent of altered arterial pressure in obese OLETF rats.

Rodriguez R, Moreno M, Lee AY, Godoy-Lugo JA, Nakano D, Nishiyama A, Parkes D, Awayda MS, Ortiz RM.

Hypertens Res. 2018 Oct;41(10):798-808. doi: 10.1038/s41440-018-0070-0. Epub 2018 Jul 9.

7.

Chronic AT1 blockade improves glucose homeostasis in obese OLETF rats.

Rodriguez R, Minas JN, Vazquez-Medina JP, Nakano D, Parkes DG, Nishiyama A, Ortiz RM.

J Endocrinol. 2018 Jun;237(3):271-284. doi: 10.1530/JOE-17-0678. Epub 2018 Apr 11.

8.

Examining Perceived Stress, Childhood Trauma and Interpersonal Trauma in Individuals With Drug Addiction.

Garami J, Valikhani A, Parkes D, Haber P, Mahlberg J, Misiak B, Frydecka D, Moustafa AA.

Psychol Rep. 2019 Apr;122(2):433-450. doi: 10.1177/0033294118764918. Epub 2018 Mar 23.

PMID:
29569991
9.

Deterministic control of magnetic vortex wall chirality by electric field.

Beardsley RP, Bowe S, Parkes DE, Reardon C, Edmonds KW, Gallagher BL, Cavill SA, Rushforth AW.

Sci Rep. 2017 Aug 8;7(1):7613. doi: 10.1038/s41598-017-07944-9.

10.

A Hydrogel-Microsphere Drug Delivery System That Supports Once-Monthly Administration of a GLP-1 Receptor Agonist.

Schneider EL, Hearn BR, Pfaff SJ, Reid R, Parkes DG, Vrang N, Ashley GW, Santi DV.

ACS Chem Biol. 2017 Aug 18;12(8):2107-2116. doi: 10.1021/acschembio.7b00218. Epub 2017 Jun 29.

PMID:
28605180
11.

Effect of lithographically-induced strain relaxation on the magnetic domain configuration in microfabricated epitaxially grown Fe81Ga19.

Beardsley RP, Parkes DE, Zemen J, Bowe S, Edmonds KW, Reardon C, Maccherozzi F, Isakov I, Warburton PA, Campion RP, Gallagher BL, Cavill SA, Rushforth AW.

Sci Rep. 2017 Feb 10;7:42107. doi: 10.1038/srep42107.

12.

Amylin/leptin synergy is absent in extreme obesity and not restored by calorie restriction-induced weight loss in rats.

Trevaskis JL, Wittmer C, Athanacio J, Griffin PS, Parkes DG, Roth JD.

Obes Sci Pract. 2016 Dec;2(4):385-391. doi: 10.1002/osp4.62. Epub 2016 Sep 7.

13.
14.

Economic reasoning and artificial intelligence.

Parkes DC, Wellman MP.

Science. 2015 Jul 17;349(6245):267-72. doi: 10.1126/science.aaa8403. Epub 2015 Jul 16. Review.

PMID:
26185245
15.

Amylin: Pharmacology, Physiology, and Clinical Potential.

Hay DL, Chen S, Lutz TA, Parkes DG, Roth JD.

Pharmacol Rev. 2015 Jul;67(3):564-600. doi: 10.1124/pr.115.010629. Review.

16.

Synergistic metabolic benefits of an exenatide analogue and cholecystokinin in diet-induced obese and leptin-deficient rodents.

Trevaskis JL, Sun C, Athanacio J, D'Souza L, Samant M, Tatarkiewicz K, Griffin PS, Wittmer C, Wang Y, Teng CH, Forood B, Parkes DG, Roth JD.

Diabetes Obes Metab. 2015 Jan;17(1):61-73. doi: 10.1111/dom.12390. Epub 2014 Oct 14.

PMID:
25204356
17.

Glaciers. Attribution of global glacier mass loss to anthropogenic and natural causes.

Marzeion B, Cogley JG, Richter K, Parkes D.

Science. 2014 Aug 22;345(6199):919-21. doi: 10.1126/science.1254702. Epub 2014 Aug 14.

18.

The glucagon-like peptide-1-based therapeutics exenatide and saxagliptin did not cause detrimental effects on the pancreas in mice, rats, dogs and monkeys.

Roy D, Chadwick KD, Tatarkiewicz K, LaCerte C, Bergholm AM, Brodie T, Mangipudy RS, Parkes D, Graziano MJ, Reilly TP.

Diabetes Obes Metab. 2014 Oct;16(10):910-21. doi: 10.1111/dom.12294. Epub 2014 Apr 27.

PMID:
24666399
19.

Novel exenatide analogs with peptidic albumin binding domains: potent anti-diabetic agents with extended duration of action.

Levy OE, Jodka CM, Ren SS, Mamedova L, Sharma A, Samant M, D'Souza LJ, Soares CJ, Yuskin DR, Jin LJ, Parkes DG, Tatarkiewicz K, Ghosh SS.

PLoS One. 2014 Feb 4;9(2):e87704. doi: 10.1371/journal.pone.0087704. eCollection 2014.

20.

Long-term metabolic benefits of exenatide in mice are mediated solely via the known glucagon-like peptide 1 receptor.

Tatarkiewicz K, Sablan EJ, Polizzi CJ, Villescaz C, Parkes DG.

Am J Physiol Regul Integr Comp Physiol. 2014 Apr 1;306(7):R490-8. doi: 10.1152/ajpregu.00495.2013. Epub 2014 Jan 29.

21.

Combined antidiabetic benefits of exenatide and dapagliflozin in diabetic mice.

Tatarkiewicz K, Polizzi C, Villescaz C, D'Souza LJ, Wang Y, Janssen S, Parkes DG.

Diabetes Obes Metab. 2014 Apr;16(4):376-80. doi: 10.1111/dom.12237. Epub 2013 Dec 9.

22.

Improved glucose control and reduced body weight in rodents with dual mechanism of action peptide hybrids.

Trevaskis JL, Mack CM, Sun C, Soares CJ, D'Souza LJ, Levy OE, Lewis DY, Jodka CM, Tatarkiewicz K, Gedulin B, Gupta S, Wittmer C, Hanley M, Forood B, Parkes DG, Ghosh SS.

PLoS One. 2013 Oct 22;8(10):e78154. doi: 10.1371/journal.pone.0078154. eCollection 2013.

23.

Bifunctional PEGylated exenatide-amylinomimetic hybrids to treat metabolic disorders: an example of long-acting dual hormonal therapeutics.

Sun C, Trevaskis JL, Jodka CM, Neravetla S, Griffin P, Xu K, Wang Y, Parkes DG, Forood B, Ghosh SS.

J Med Chem. 2013 Nov 27;56(22):9328-41. doi: 10.1021/jm401418s. Epub 2013 Nov 6.

PMID:
24144329
24.

Magnetostrictive thin films for microwave spintronics.

Parkes DE, Shelford LR, Wadley P, Holý V, Wang M, Hindmarch AT, van der Laan G, Campion RP, Edmonds KW, Cavill SA, Rushforth AW.

Sci Rep. 2013;3:2220. doi: 10.1038/srep02220.

25.

A novel long-acting glucose-dependent insulinotropic peptide analogue: enhanced efficacy in normal and diabetic rodents.

Tatarkiewicz K, Hargrove DM, Jodka CM, Gedulin BR, Smith PA, Hoyt JA, Lwin A, Collins L, Mamedova L, Levy OE, D'Souza L, Janssen S, Srivastava V, Ghosh SS, Parkes DG.

Diabetes Obes Metab. 2014 Jan;16(1):75-85. doi: 10.1111/dom.12181. Epub 2013 Aug 19.

26.

Discovery and development of exenatide: the first antidiabetic agent to leverage the multiple benefits of the incretin hormone, GLP-1.

Parkes DG, Mace KF, Trautmann ME.

Expert Opin Drug Discov. 2013 Feb;8(2):219-44. doi: 10.1517/17460441.2013.741580. Epub 2012 Dec 12. Review.

PMID:
23231438
27.

Effects of amylin and bupropion/naltrexone on food intake and body weight are interactive in rodent models.

Clapper JR, Athanacio J, Wittmer C, Griffin PS, D'Souza L, Parkes DG, Roth JD.

Eur J Pharmacol. 2013 Jan 5;698(1-3):292-8. doi: 10.1016/j.ejphar.2012.11.010. Epub 2012 Nov 21.

PMID:
23178527
28.

No evidence of drug-induced pancreatitis in rats treated with exenatide for 13 weeks.

Tatarkiewicz K, Belanger P, Gu G, Parkes D, Roy D.

Diabetes Obes Metab. 2013 May;15(5):417-26. doi: 10.1111/dom.12040. Epub 2012 Dec 7.

29.

GLP-1 receptor activated insulin secretion from pancreatic β-cells: mechanism and glucose dependence.

Meloni AR, DeYoung MB, Lowe C, Parkes DG.

Diabetes Obes Metab. 2013 Jan;15(1):15-27. doi: 10.1111/j.1463-1326.2012.01663.x. Epub 2012 Aug 1. Review.

30.

Interactions of amylinergic and melanocortinergic systems in the control of food intake and body weight in rodents.

Roth JD, D'Souza L, Griffin PS, Athanacio J, Trevaskis JL, Nazarbaghi R, Jodka C, Athanacio J, Hoyt J, Forood B, Parkes DG.

Diabetes Obes Metab. 2012 Jul;14(7):608-15. doi: 10.1111/j.1463-1326.2012.01570.x. Epub 2012 Feb 20.

PMID:
22276636
31.

Glucagon-like peptide-1 receptor agonism improves metabolic, biochemical, and histopathological indices of nonalcoholic steatohepatitis in mice.

Trevaskis JL, Griffin PS, Wittmer C, Neuschwander-Tetri BA, Brunt EM, Dolman CS, Erickson MR, Napora J, Parkes DG, Roth JD.

Am J Physiol Gastrointest Liver Physiol. 2012 Apr 15;302(8):G762-72. doi: 10.1152/ajpgi.00476.2011. Epub 2012 Jan 19.

32.

Glucoregulatory effects and prolonged duration of action of davalintide: a novel amylinomimetic peptide.

Mack CM, Smith PA, Athanacio JR, Xu K, Wilson JK, Reynolds JM, Jodka CM, Lu MG, Parkes DG.

Diabetes Obes Metab. 2011 Dec;13(12):1105-13. doi: 10.1111/j.1463-1326.2011.01465.x.

PMID:
21733060
33.

GLP-1R and amylin agonism in metabolic disease: complementary mechanisms and future opportunities.

Roth JD, Erickson MR, Chen S, Parkes DG.

Br J Pharmacol. 2012 May;166(1):121-36. doi: 10.1111/j.1476-5381.2011.01537.x. Review.

34.

Glucagon-like peptide-1 and the exenatide analogue AC3174 improve cardiac function, cardiac remodeling, and survival in rats with chronic heart failure.

Liu Q, Anderson C, Broyde A, Polizzi C, Fernandez R, Baron A, Parkes DG.

Cardiovasc Diabetol. 2010 Nov 16;9:76. doi: 10.1186/1475-2840-9-76.

35.

Enhanced amylin-mediated body weight loss in estradiol-deficient diet-induced obese rats.

Trevaskis JL, Turek VF, Wittmer C, Griffin PS, Wilson JK, Reynolds JM, Zhao Y, Mack CM, Parkes DG, Roth JD.

Endocrinology. 2010 Dec;151(12):5657-68. doi: 10.1210/en.2010-0590. Epub 2010 Oct 20.

PMID:
20962049
36.

Exenatide does not evoke pancreatitis and attenuates chemically induced pancreatitis in normal and diabetic rodents.

Tatarkiewicz K, Smith PA, Sablan EJ, Polizzi CJ, Aumann DE, Villescaz C, Hargrove DM, Gedulin BR, Lu MG, Adams L, Whisenant T, Roy D, Parkes DG.

Am J Physiol Endocrinol Metab. 2010 Dec;299(6):E1076-86. doi: 10.1152/ajpendo.00479.2010. Epub 2010 Oct 5.

37.

The exenatide analogue AC3174 attenuates hypertension, insulin resistance, and renal dysfunction in Dahl salt-sensitive rats.

Liu Q, Adams L, Broyde A, Fernandez R, Baron AD, Parkes DG.

Cardiovasc Diabetol. 2010 Aug 3;9:32. doi: 10.1186/1475-2840-9-32.

38.

Insights into amylin-leptin synergy.

Trevaskis JL, Parkes DG, Roth JD.

Trends Endocrinol Metab. 2010 Aug;21(8):473-9. doi: 10.1016/j.tem.2010.03.006. Epub 2010 Apr 21. Review.

PMID:
20413324
39.

Multi-hormonal weight loss combinations in diet-induced obese rats: therapeutic potential of cholecystokinin?

Trevaskis JL, Turek VF, Griffin PS, Wittmer C, Parkes DG, Roth JD.

Physiol Behav. 2010 May 11;100(2):187-95. doi: 10.1016/j.physbeh.2010.02.023. Epub 2010 Mar 3.

PMID:
20206194
40.

"Weighing in" on synergy: preclinical research on neurohormonal anti-obesity combinations.

Roth JD, Trevaskis JL, Turek VF, Parkes DG.

Brain Res. 2010 Sep 2;1350:86-94. doi: 10.1016/j.brainres.2010.01.027. Epub 2010 Jan 21. Review.

PMID:
20096672
41.

Davalintide (AC2307), a novel amylin-mimetic peptide: enhanced pharmacological properties over native amylin to reduce food intake and body weight.

Mack CM, Soares CJ, Wilson JK, Athanacio JR, Turek VF, Trevaskis JL, Roth JD, Smith PA, Gedulin B, Jodka CM, Roland BL, Adams SH, Lwin A, Herich J, Laugero KD, Vu C, Pittner R, Paterniti JR Jr, Hanley M, Ghosh S, Parkes DG.

Int J Obes (Lond). 2010 Feb;34(2):385-95. doi: 10.1038/ijo.2009.238. Epub 2009 Nov 24.

PMID:
19935749
42.

Mechanisms of amylin/leptin synergy in rodent models.

Turek VF, Trevaskis JL, Levin BE, Dunn-Meynell AA, Irani B, Gu G, Wittmer C, Griffin PS, Vu C, Parkes DG, Roth JD.

Endocrinology. 2010 Jan;151(1):143-52. doi: 10.1210/en.2009-0546. Epub 2009 Oct 29.

PMID:
19875640
43.

Interaction of leptin and amylin in the long-term maintenance of weight loss in diet-induced obese rats.

Trevaskis JL, Lei C, Koda JE, Weyer C, Parkes DG, Roth JD.

Obesity (Silver Spring). 2010 Jan;18(1):21-6. doi: 10.1038/oby.2009.187. Epub 2009 Jun 18.

44.

Exenatide improves hypertension in a rat model of the metabolic syndrome.

Laugero KD, Stonehouse AH, Guss S, Landry J, Vu C, Parkes DG.

Metab Syndr Relat Disord. 2009 Aug;7(4):327-34. doi: 10.1089/met.2008.0095.

PMID:
19320558
45.

Amylin-mediated restoration of leptin responsiveness in diet-induced obesity: magnitude and mechanisms.

Trevaskis JL, Coffey T, Cole R, Lei C, Wittmer C, Walsh B, Weyer C, Koda J, Baron AD, Parkes DG, Roth JD.

Endocrinology. 2008 Nov;149(11):5679-87. doi: 10.1210/en.2008-0770. Epub 2008 Jul 31.

PMID:
18669592
46.

Antiobesity effects of the beta-cell hormone amylin in combination with phentermine or sibutramine in diet-induced obese rats.

Roth JD, Trevaskis JL, Wilson J, Lei C, Athanacio J, Mack C, Kesty NC, Coffey T, Weyer C, Parkes DG.

Int J Obes (Lond). 2008 Aug;32(8):1201-10. doi: 10.1038/ijo.2008.91. Epub 2008 Jun 17.

PMID:
18560368
47.

Leptin responsiveness restored by amylin agonism in diet-induced obesity: evidence from nonclinical and clinical studies.

Roth JD, Roland BL, Cole RL, Trevaskis JL, Weyer C, Koda JE, Anderson CM, Parkes DG, Baron AD.

Proc Natl Acad Sci U S A. 2008 May 20;105(20):7257-62. doi: 10.1073/pnas.0706473105. Epub 2008 May 5.

48.

Pharmacokinetics and pharmacodynamics of exenatide following alternate routes of administration.

Gedulin BR, Smith PA, Jodka CM, Chen K, Bhavsar S, Nielsen LL, Parkes DG, Young AA.

Int J Pharm. 2008 May 22;356(1-2):231-8. doi: 10.1016/j.ijpharm.2008.01.015. Epub 2008 Jan 17.

PMID:
18291606
49.

Pharmacological actions of the peptide hormone amylin in the long-term regulation of food intake, food preference, and body weight.

Mack C, Wilson J, Athanacio J, Reynolds J, Laugero K, Guss S, Vu C, Roth J, Parkes D.

Am J Physiol Regul Integr Comp Physiol. 2007 Nov;293(5):R1855-63. Epub 2007 Sep 12.

50.

Combination therapy with amylin and peptide YY[3-36] in obese rodents: anorexigenic synergy and weight loss additivity.

Roth JD, Coffey T, Jodka CM, Maier H, Athanacio JR, Mack CM, Weyer C, Parkes DG.

Endocrinology. 2007 Dec;148(12):6054-61. Epub 2007 Aug 30.

PMID:
17761760

Supplemental Content

Loading ...
Support Center